PMC7425317_01
Erosions with serous and haemorrhagic crusts with oedematous tissue in the right intranasal cavity.
10.1177_2050313X20935736-fig1.jpg
PMC7425317_01_10.1177_2050313X20935736-fig1.jpg
fig1-2050313X20935736
Lesions were located on the trunk, lower leg, and intranasal cavity (Figure 1), with several crusted and necrotic plaques.
HPS staining of the skin biopsy at 10X showing a large abscess in the dermis surrounded by a mixed inflammatory infiltrate (lymphocytes, histiocyte and plasma cells).
10.1177_2050313X20935736-fig2.jpg
PMC7425317_01_10.1177_2050313X20935736-fig2.jpg
fig2-2050313X20935736
The skin biopsy showed large abscesses in the dermis, surrounded by a mixed inflammatory infiltrate (lymphocytes, macrophages, plasma cells) (Figure 2).
Multiple deep, large and cribriform ulcers with erythemato-violaceous undermined borders sparse on the trunk with two crusted necrotic plaques on the left lower abdomen.
10.1177_2050313X20935736-fig3.jpg
PMC7425317_01_10.1177_2050313X20935736-fig3.jpg
fig3-2050313X20935736
Despite courses of topical, intralesional and oral corticosteroids treatments, the lesions worsened and reached a total of 18, mostly located on the trunk and the lower extremities (Figure 3).
Reepithelialisation with atrophic cribriform scars following the introduction of infliximab.
10.1177_2050313X20935736-fig4.jpg
PMC7425317_01_10.1177_2050313X20935736-fig4.jpg
fig4-2050313X20935736
Infliximab was eventually introduced, and he had a gradual re-epithelialization with atrophic cribriform scars (Figure 4).
PMC7425317_02
Multiple well-circumscribed atrophic and hyperpigmented scars with telangiectasias on the back with several punched out ulcers within these scars. These ulcers represent signs of relapses of the lesions at the time of consultation.
10.1177_2050313X20935736-fig5.jpg
PMC7425317_02_10.1177_2050313X20935736-fig5.jpg
fig5-2050313X20935736
He presented with up to 22 cribriform ulcers and atrophic scars mostly located on the trunk, with two lesions in the pre-auricular region (Figure 5).